Vaccine Adjuvants and Innate Immune Sensing

Vaccine adjuvants and innate immune sensing encompass the biochemical delivery systems and molecular immunopotentiators formulated into non-living vaccines (including recombinant subunit, toxoid, and polysaccharide-protein conjugate platforms) to increase the magnitude, breadth, and durability of adaptive immunology. Named from the Latin adjuvare ("to help") by Gaston Ramon in 1925 and famously characterized by immunologist Charles Janeway Jr. (1989) as "the immunologist's dirty little secret," adjuvants bridge innate pathogen recognition and lymphocyte clonal expansion.

Whereas live-attenuated vaccines contain endogenous viral or bacterial nucleic acids and cell-wall components that naturally trigger innate immunity, purified recombinant proteins administered in saline provide Signal 1 (peptide–major histocompatibility complex [MHC] engagement of the T-cell receptor) without Signal 2 (upregulation of CD80, CD86, and CD40 costimulatory receptors on dendritic cells) or Signal 3 (lineage-polarizing cytokines such as IL-12, IFN-γ, IL-4, and IL-21). Without an adjuvant to activate innate Pattern Recognition Receptors (PRRs)—including Toll-like receptors (TLRs), NOD-like receptors (NLRs), C-type lectin receptors, RIG-I-like helicases, and the cGAS–STING pathway—soluble protein antigens induce T-cell anergy or transient, low-affinity antibody titers.

Aluminum Salts (Alum): Crystal Chemistry, Ligand Exchange, and NLRP3 Activation

Introduced in 1926 by chemist Alexander Glenny when he precipitated diphtheria toxoid with potassium alum, particulate aluminum salts remain the most widely used human adjuvants. Clinical formulations do not use chemical alum (KAl(SO₄)₂), but rather two distinct mineral phases with opposite surface charges at physiological pH (7.4):

• Aluminum Oxyhydroxide (AlOOH, Alhydrogel): Poorly crystalline boehmite nanofibers with a point of zero charge (PZC) ≈ 11.4, carrying a net positive surface charge at pH 7.4 that electrostatically adsorbs anionic protein antigens (isoelectric point pI < 7.4) and exchanges surface hydroxyl (–OH) groups for phosphorylated antigen side chains (ligand exchange).
• Aluminum Hydroxyphosphate (Al(OH)_x(PO₄)_y, Adju-Phos): Amorphous platelets in which phosphate groups substitute for hydroxyls, lowering the PZC to 4.5–7.0 and conferring a net negative surface charge at pH 7.4 that binds cationic antigens.

For decades, alum was assumed to function simply as an extracellular antigen depot that slowly released antigen over weeks. Experimental excision of the injection site nodule 2 hours after immunization, however, does not diminish systemic T- or B-cell responses, refuting the passive depot model. Instead, alum operates by inducing localized damage-associated molecular patterns (DAMPs) and innate inflammasome signaling:

1. Necroptotic DAMP Release (Uric Acid and Host DNA): Contact between alum microcrystals and resident myocytes or macrophages triggers plasma membrane lipid sorting and localized cell death, releasing endogenous monosodium urate (uric acid) crystals and extracellular host DNA (which activates the cytosolic STING–TBK1–IRF3 pathway to drive T_FH differentiation).
2. Phagolysosomal Rupture and the NLRP3 Inflammasome: When infiltrating monocytes and dendritic cells phagocytose alum crystals, crystal-induced swelling and rupture of the acidified phagolysosome release the cysteine protease cathepsin B and K⁺ efflux into the cytoplasm. Cytosolic cathepsin B triggers oligomerization of the NLRP3 inflammasome (NLRP3 + ASC adaptor + pro-caspase-1), activating caspase-1 to cleave pro-IL-1β and pro-IL-18 into bioactive cytokines. Because alum does not induce IL-12, it biases CD4⁺ T cells toward a Th2 humoral profile (IgG1 and IgE in mice; IgG1 and IgG4 in humans) with minimal CD8⁺ cytotoxic T-cell priming.

Oil-in-Water Squalene Nanoemulsions (MF59 and AS03)

To overcome the weak immunogenicity of seasonal and pandemic influenza vaccines in older adults, oil-in-water nanoemulsions disperse 160-nm droplets of biodegradable squalene (C₃₀H₅₀, a naturally occurring triterpene intermediate in human cholesterol biosynthesis purified from shark liver oil) stabilized by the non-ionic surfactants polysorbate 80 (Tween 80) and sorbitan trioleate (Span 85):

• MF59 (Fluad): Squalene nanoemulsion that acts independently of individual TLRs via a MyD88-dependent ATP-release pathway. Intramuscular injection induces transient release of endogenous extracellular ATP from muscle fibers and resident macrophages, driving a potent chemokine cascade (CCL2, CCL3, CCL4, and CXCL8) that recruits monocytes, eosinophils, and neutrophils, accelerates monocyte differentiation into migratory CD11c⁺ dendritic cells, and broadens germinal center epitope spreading across drifted influenza hemagglutinin variants.
• AS03 (Pandemrix, Arepanrix, SKYcovione): Adds DL-α-tocopherol (Vitamin E, 11.86 mg/dose) as an immunostimulatory co-oil to the squalene emulsion, enhancing NF-κB activation, antigen loading in draining lymph node monocytes, and multi-clade cross-neutralizing antibody breadth.

Monophosphoryl Lipid A (MPL), Saponins (QS-21, Matrix-M), and GSK Adjuvant Systems (AS01, AS04)

Because clearing intracellular pathogens (such as Mycobacterium tuberculosis, Plasmodium falciparum, herpes zoster, and respiratory viruses) requires interferon-γ-secreting CD4⁺ Th1 cells and cytotoxic CD8⁺ T cells, rational adjuvant design pairs particulate delivery systems with chemically defined PRR ligands:

• Monophosphoryl Lipid A (MPL): Gram-negative bacterial lipopolysaccharide (LPS) is a potent agonist of cell-surface and endosomal TLR4, but unmodified Lipid A is too pyrogenic for human injection. By subjecting Salmonella minnesota R595 LPS to sequential acid and base hydrolysis, Edgar Ribi removed the core polysaccharide, the 3-O-linked acyl chain, and the 1-phosphate group of the glucosamine disaccharide backbone, yielding 3-O-desacyl-4'-monophosphoryl lipid A (MPL). Removing the 1-phosphate group reduces endotoxicity ~1,000-fold by biasing TLR4 dimer signaling away from the pro-inflammatory MyD88 adaptor and toward the TRIF–IRF3 pathway. In AS04 (used in Cervarix and Fendrix), MPL is adsorbed onto aluminum salt.
• AS01 (Liposomal MPL + QS-21): Formulates MPL and QS-21—a purified amphipathic triterpene glycoside saponin extracted from the bark of the South American soapbark tree Quillaja saponaria—into 100-nm dioleoylphosphatidylcholine (DOPC) and cholesterol liposomes (wherein liposomal cholesterol quenches the hemolytic toxicity of free QS-21 against erythrocyte membranes).
• Synergistic Mechanism in the Draining Lymph Node: Upon intramuscular injection, AS01 liposomes drain within minutes to the subcapsular sinus of the lymph node and are internalized by CD169⁺ subcapsular sinus macrophages. Inside the endolysosome, QS-21 binds membrane cholesterol to form pores that destabilize the phagolysosomal membrane, activating caspase-1 to release a burst of IL-18, while MPL engages TLR4 to stimulate IL-12 production. Together, IL-18 and IL-12 trigger resident natural killer (NK) cells and innate CD8⁺ T cells to secrete an early wave of IFN-γ within 6 to 24 hours, which licenses infiltrating monocytes and XCR1⁺ conventional dendritic cells (cDC1). Simultaneously, QS-21-mediated endolysosomal pore formation allows co-delivered exogenous protein antigen to escape into the cytosol of cDC1 cells for proteasomal degradation and MHC Class I cross-presentation—explaining why AS01 achieves >91%–97% efficacy against shingles (Shingrix) and 82.6% efficacy against RSV lower respiratory tract disease in older adults (Arexvy).
• Matrix-M: Formulates two purified Quillaja saponaria saponin fractions (Fraction A [85%, lower reactogenicity] and Fraction C [15%, high immunostimulatory potency]) with cholesterol and phosphatidylcholine into 40-nm icosahedral cage-like nanoparticles (immunostimulating complexes, ISCOM-Matrix) without covalently binding the antigen, powering the Novavax COVID-19 and R21/Matrix-M malaria vaccines.

Nucleic Acid and Small-Molecule Endosomal TLR Agonists (CpG 1018 and Alhydroxiquim-II)

• CpG 1018 (TLR9 Agonist): Bacterial DNA contains unmethylated cytidine-phosphate-guanosine (CpG) dinucleotide motifs at a 20-fold higher frequency than vertebrate genomic DNA. CpG 1018 is a synthetic 22-mer oligodeoxynucleotide (5'-TGACTGTGAACGTTCGAGATGA-3') synthesized with a nuclease-resistant phosphorothioate backbone that agonizes endosomal TLR9 in human plasmacytoid dendritic cells (pDCs) and B cells, activating MyD88 → IRAK4 → IRF7 and NF-κB to drive type I interferon (IFN-α) and rapid B-cell differentiation. In Heplisav-B, pairing recombinant HBsAg with 3,000 μg of CpG 1018 achieves higher seroprotection rates after 2 doses over 1 month (90%–100%, including in diabetics and older adults) than 3 doses of alum-adjuvanted Engerix-B over 6 months (70.5%).
• Alhydroxiquim-II (TLR7/8 Agonist): Small-molecule synthetic imidazoquinolines (such as resiquimod) potently activate endosomal TLR7 (in pDCs and B cells) and TLR8 (in myeloid cDCs and monocytes), but unmodified small molecules diffuse rapidly across capillary walls into the systemic circulation, causing systemic febrile cytokine storms. Alhydroxiquim-II (used in the inactivated SARS-CoV-2 vaccine Covaxin [BBV152]) attaches a phosphonate-terminated polyethylene glycol linker to an imidazoquinoline core so the molecule binds tightly to aluminum oxyhydroxide via ligand exchange, restricting TLR7/8 activation to the draining lymph node and polarizing a pure Th1 IgG1 response without systemic toxicity.

Why did the classic "antigen depot" hypothesis fail to explain how aluminum salt adjuvants work?

In 1926, Alexander Glenny proposed that alum enhanced antibody titers by precipitating soluble antigen at the injection site and slowly releasing it over weeks. However, experiments by Hutchison and colleagues (2012) demonstrated that surgically removing the entire injection site ear pinna 2 hours after alum-antigen immunization had zero negative effect on antigen-specific T-cell expansion or serum IgG titers. Instead, alum functions by inducing immediate necroptotic release of endogenous danger signals (uric acid and host DNA) and triggering phagolysosomal rupture and NLRP3 inflammasome activation in migratory dendritic cells that rapidly traffic to the draining lymph node.

How does liposomal cholesterol in AS01 eliminate the hemolytic toxicity of free QS-21 saponin?

Unformulated Quillaja saponaria saponin (QS-21) is an amphipathic triterpene glycoside with high affinity for membrane cholesterol; when injected in saline, free QS-21 intercalates into the plasma membrane of red blood cells and muscle cells, forming irreversible cholesterol-saponin pores that cause severe injection-site pain and hemolysis. In the AS01 adjuvant system, QS-21 is pre-formulated into dioleoylphosphatidylcholine (DOPC) liposomes containing excess cholesterol, which saturates QS-21's cholesterol-binding motif in the vial so it cannot lyse extracellular host membranes, while still allowing intracellular endolysosomal destabilization and cross-presentation once the liposome is endocytosed by lymph node macrophages.

Why had small-molecule TLR7/8 agonists failed as parenteral vaccine adjuvants prior to Alhydroxiquim-II?

Synthetic imidazoquinolines (such as imiquimod and resiquimod) have low molecular weights (~240–315 Da). When injected intramuscularly in aqueous solution, they do not co-localize with the macromolecular protein antigen in lymphatic vessels; instead, they diffuse across blood capillary endothelia into the systemic circulation within minutes, triggering widespread TLR7/8 activation in peripheral leukocytes and causing dose-limiting systemic fevers, lymphopenia, and flu-like symptoms. Tethering the imidazoquinoline to particulate aluminum oxyhydroxide via a phosphonate group (Alhydroxiquim-II) anchors the agonist so it travels solely with phagocytosed antigen to the draining lymph node.

1. Pulendran, B., S. Arunachalam, P., & O'Hagan, D. T. (2021). Emerging concepts in the science of vaccine adjuvants. Nature Reviews Drug Discovery, 20(6), 454–475. https://doi.org/10.1038/s41573-021-00163-y
2. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 453(7198), 1122–1126. https://doi.org/10.1038/nature06939
3. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., & Garçon, N. (2009). AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Journal of Immunology, 183(10), 6186–6197. https://doi.org/10.4049/jimmunol.0901474
4. Detienne, S., Welsby, I., Collignon, C., Wouters, S., Coccia, M., Delhaye, S., Vanonen, L., Bosmans, F.,ori, M., Pascolo, S., Didierlaurent, A. M., & Goriely, S. (2016). Central role of CD169⁺ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Scientific Reports, 6, 39475. https://doi.org/10.1038/srep39475